The appellants sought to certify a class proceeding against pharmaceutical companies for negligently manufacturing valsartan, alleging contamination with NDMA and NDEA, which are potential carcinogens.
The claim was for damages related to an increased risk of cancer, costs of medical services and monitoring, refunds for drugs, and psychological damages.
The motion judge dismissed the certification, finding no viable cause of action based on concrete injury.
The Court of Appeal dismissed the appeal, affirming that claims for genotoxic injury (molecular changes without perceptible effect), psychological harm (not meeting the 'serious and prolonged' or 'ordinary fortitude' thresholds), and pure economic loss (as the product was discarded and not imminently dangerous) were not compensable in tort.
The court also upheld the dismissal of claims for battery, consumer protection breaches, Competition Act breaches, and unjust enrichment, concluding that the pleadings did not disclose viable causes of action or meet commonality criteria for certification.